93 results
8-K
EX-99.1
NAMS
NewAmsterdam Pharma Company NV
11 Jun 24
NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United
8:12am
benefits of obicetrapib’s scientific innovation years beyond potential FDA approval.”
About Obicetrapib
Obicetrapib is a novel, oral, low-dose CETP
DEF 14A
NAMS
NewAmsterdam Pharma Company NV
9 May 24
Definitive proxy
4:15pm
to participate in our equity incentive plans, including the Company’s long-term incentive plan (the “LTIP”), and other employee benefits and insurance … and benefits described above. In addition, all of Dr. Davidson’s time-based stock options and equity awards will accelerate, becoming fully exercisable
10-Q
2024 Q1
NAMS
NewAmsterdam Pharma Company NV
8 May 24
Quarterly report
4:30pm
)
March 31,2024
December 31,2023
Accrued research and development materials and services
Accrued compensation and benefits
Accrued professional fees … healthcare providers and patients about the benefits, risks, administration and use of obicetrapib, if approved;
acceptance of obicetrapib
PRE 14A
NAMS
NewAmsterdam Pharma Company NV
29 Apr 24
Preliminary proxy
5:00pm
, including the Company’s long-term incentive plan (the “LTIP”), and other employee benefits and insurance programs generally made available to our full-time … following such Change in Control, Dr. Davidson will be entitled to receive the severance payments and benefits described above. In addition, all
424B3
NAMS
NewAmsterdam Pharma Company NV
19 Apr 24
Prospectus supplement
4:21pm
to the Ordinary Shares that go beyond ordinary asset management (normaal, actief vermogensbeheer) or otherwise derives benefits from the Ordinary … Shares that are taxable as benefits from miscellaneous activities (resultaat uit overige werkzaamheden).
Taxation of savings and investments
POS AM
dlyx2xwws
12 Apr 24
Prospectus update (post-effective amendment)
4:15pm
POS AM
EX-5.2
wsgz775ypl77w6yws1ae
12 Apr 24
Prospectus update (post-effective amendment)
4:15pm
424B3
y629km0kduw6uc
12 Mar 24
Prospectus supplement
4:18pm
POS AM
EX-5.2
bskys9khos30j7w7
28 Feb 24
Prospectus update (post-effective amendment)
5:01pm
POS AM
xgp7 e9ib
28 Feb 24
Prospectus update (post-effective amendment)
5:01pm
10-K
EX-10.4
lu8kwt
28 Feb 24
Annual report
8:00am
10-K
EX-10.8
yx0gg go8q1p3
28 Feb 24
Annual report
8:00am
10-K
EX-10.7
cgg euror18
28 Feb 24
Annual report
8:00am
10-K
2tqhl1fmd
28 Feb 24
Annual report
8:00am
10-K
EX-97.1
ih27nhl dw
28 Feb 24
Annual report
8:00am
10-K
EX-10.9
s0z9j7
28 Feb 24
Annual report
8:00am
8-K
EX-5.2
nracs
15 Feb 24
NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
4:18pm
8-K
EX-1.1
ehz bf7udt
15 Feb 24
NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
4:18pm
424B5
7gjg5v2d5u7e1
15 Feb 24
Prospectus supplement for primary offering
4:15pm
424B5
61j10yprxl2g
13 Feb 24
Prospectus supplement for primary offering
5:19pm